These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 34800174)

  • 1. Real-world effectiveness and rheumatologist satisfaction with secukinumab in the treatment of patients with axial spondyloarthritis.
    Kiltz U; Keininger DL; Holdsworth EA; Booth N; Howell O; Modi N; Tian H; Conaghan PG
    Clin Rheumatol; 2022 Feb; 41(2):471-481. PubMed ID: 34800174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of secukinumab in radiographic and non-radiographic axial spondyloarthritis: a European routine-care observational study.
    Christiansen SN; Horskjær Rasmussen S; Ostergaard M; Pons M; Michelsen B; Pavelka K; Codreanu C; Ciurea A; Glintborg B; Santos MJ; Sari I; Rotar Z; Gudbjornsson B; Macfarlane GJ; Relas H; Iannone F; Laas K; Wallman JK; van de Sande M; Provan SA; Castrejon I; Zavada J; Mogosan C; Nissen MJ; Loft AG; Barcelos A; Erez Y; Pirkmajer KP; Grondal G; Jones GT; Hokkanen AM; Chimenti MS; Vorobjov S; Di Giuseppe D; Kvien TK; Otero-Varela L; van der Horst-Bruinsma I; Hetland ML; Ørnbjerg LM
    RMD Open; 2024 Jul; 10(3):. PubMed ID: 39053949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real world effectiveness and satisfaction with secukinumab in the treatment of patients with psoriatic arthritis: a population survey in five European countries.
    Conaghan PG; Keininger DL; Holdsworth EA; Booth N; Modi NN; Tian H; Kiltz U
    Curr Med Res Opin; 2021 Oct; 37(10):1845-1853. PubMed ID: 34256669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing symptoms, treatment patterns, and quality of life of ankylosing spondylitis and non-radiographic axial spondyloarthritis patients in the USA: findings from a patient and rheumatologist Survey.
    Hunter T; Sandoval D; Booth N; Holdsworth E; Deodhar A
    Clin Rheumatol; 2021 Aug; 40(8):3161-3167. PubMed ID: 33611647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration.
    Michelsen B; Lindström U; Codreanu C; Ciurea A; Zavada J; Loft AG; Pombo-Suarez M; Onen F; Kvien TK; Rotar Z; Santos MJ; Iannone F; Hokkanen AM; Gudbjornsson B; Askling J; Ionescu R; Nissen MJ; Pavelka K; Sanchez-Piedra C; Akar S; Sexton J; Tomsic M; Santos H; Sebastiani M; Österlund J; Geirsson AJ; Macfarlane G; van der Horst-Bruinsma I; Georgiadis S; Brahe CH; Ørnbjerg LM; Hetland ML; Østergaard M
    RMD Open; 2020 Sep; 6(3):. PubMed ID: 32950963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Four-year real-world experience of secukinumab in a large Italian cohort of axial spondyloarthritis.
    Ramonda R; Lorenzin M; Chimenti MS; D'Angelo S; Marchesoni A; Selmi C; Lubrano E; Santo L; Luchetti Gentiloni MM; Atzeni F; Cauli A; Manara M; Rossini M; Foti R; Cozzi G; Scagnellato L; Ferraioli M; Carriero A; Luciano N; Ruzzon F; Fatica M; Fracassi E; Doria A; Foti R; Carletto A
    Front Immunol; 2024; 15():1435599. PubMed ID: 39076975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient-reported outcomes in axial spondyloarthritis and psoriatic arthritis patients treated with secukinumab for 24 months in daily clinical practice.
    Christiansen SN; Horskjær Rasmussen S; Pons M; Michelsen B; Glintborg B; Gudbjornsson B; Grondal G; Vencovsky J; Loft AG; Rotar Z; Pirkmajer KP; Nissen MJ; Baranová J; Macfarlane GJ; Jones GT; Iannone F; Caporali R; Laas K; Vorobjov S; Giuseppe DD; Olofsson T; Provan SA; Fagerli KM; Castrejon I; Otero-Varela L; van de Sande M; van der Horst-Bruinsma I; Nordström D; Kuusalo L; Bernardes M; Hetland ML; Østergaard M; Midtbøll Ørnbjerg L
    Semin Arthritis Rheum; 2024 Apr; 65():152388. PubMed ID: 38301349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonsteroidal anti-inflammatory drug-sparing effect of secukinumab in patients with radiographic axial spondyloarthritis: 4-year results from the MEASURE 2, 3 and 4 phase III trials.
    Dougados M; Kiltz U; Kivitz A; Pavelka K; Rohrer S; McCreddin S; Quebe-Fehling E; Porter B; Talloczy Z
    Rheumatol Int; 2022 Feb; 42(2):205-213. PubMed ID: 34773130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world experience with secukinumab in the entire axial spondyloarthritis spectrum.
    Sivera F; Núñez-Monje V; Campos-Fernández C; Balaguer-Trull I; Robustillo-Villarino M; Aguilar-Zamora M; Garijo-Bufort M; López-Gómez JM; Peña-González C; de la Morena I; Bedoya-Sanchís D; Yankova-Komsalova L; Conesa-Mateos A; Martínez-Cristóbal A; Navarro-Blasco FJ; Senabre-Gallego JM; Alegre-Sancho JJ
    Front Med (Lausanne); 2023; 10():1156557. PubMed ID: 37250652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Burden of illness associated with non-radiographic axial spondyloarthritis: a multiperspective European cross-sectional observational study.
    Sieper J; Holbrook T; Black CM; Wood R; Hu X; Kachroo S
    Clin Exp Rheumatol; 2016; 34(6):975-983. PubMed ID: 27749215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-World Retention and Clinical Effectiveness of Secukinumab for Axial Spondyloarthritis: Results From the Canadian Spondyloarthritis Research Network.
    Inman RD; Choquette D; Khraishi M; Gladman DD; Hussein S; Neish D; Leclerc P
    J Rheumatol; 2023 May; 50(5):634-640. PubMed ID: 36642434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early identification of axial spondyloarthritis in a multi-ethnic Asian population.
    Xiang L; Fong W; Low AHL; Leung YY; Gandhi M; Xin X; Uy EJB; Hamilton L; Thumboo J
    Clin Rheumatol; 2022 Apr; 41(4):1095-1103. PubMed ID: 34625882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and safety of 12-month certolizumab pegol treatment for axial spondyloarthritis in real-world clinical practice in Europe.
    Baraliakos X; Witte T; De Clerck L; Frediani B; Collantes-Estévez E; Katsifis G; VanLunen B; Kleine E; Hoepken B; Bauer L; Goodson N
    Rheumatology (Oxford); 2021 Jan; 60(1):113-124. PubMed ID: 32584415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing rheumatologists' attitudes and utilization of classification criteria for ankylosing spondylitis and axial spondyloarthritis: a global effort.
    Rich-Garg N; Danve A; Choi D; Vakil-Gilani K; Akkoc N; Azevedo V; Russell A; Sharma A; Cush J; Curtis JR; Deodhar A
    Clin Rheumatol; 2021 Mar; 40(3):949-954. PubMed ID: 32797363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A cross-sectional study on factors associated with poor work outcomes in patients with axial spondyloarthritis in Singapore.
    Goh Y; Kwan YH; Leung YY; Fong W; Cheung PP
    Int J Rheum Dis; 2019 Nov; 22(11):2001-2008. PubMed ID: 31576680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Benchmarking Study Evaluating Axial Spondyloarthritis Burden in Spain and Other European Countries. Results from the Spanish Atlas and the European Map of Axial Spondyloarthritis (EMAS) Studies.
    Garrido-Cumbrera M; Gratacós J; Collantes-Estevez E; Zarco-Montejo P; Sastre C; Christen L; Sanz-Gómez S; Correa-Fernández J; Navarro-Compán V
    Int J Rheum Dis; 2021 Sep; 24(9):1127-1136. PubMed ID: 34268889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA.
    van der Heijde D; Dougados M; Landewé R; Sieper J; Maksymowych WP; Rudwaleit M; Van den Bosch F; Braun J; Mease PJ; Kivitz AJ; Walsh J; Davies O; Bauer L; Hoepken B; Peterson L; Deodhar A
    Rheumatology (Oxford); 2017 Sep; 56(9):1498-1509. PubMed ID: 28498975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug Survival, Effectiveness and Safety of Secukinumab in Axial Spondyloarthritis up to 4 Years: A Real-Life Single Center Experience.
    Diaconu AD; Pomîrleanu C; Russu M; Strugariu G; Ancuța E; Ciortescu I; Bologa C; Morărașu BC; Constantin M; Ceasovschih A; Șorodoc V; Șorodoc L; Ancuța C
    J Pers Med; 2024 Apr; 14(4):. PubMed ID: 38673044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug retention rate and predictive factors of drug survival for secukinumab in radiographic axial spondyloarthritis.
    Armağan B; Kılıç L; Farisoğulları B; Yardımcı GK; Bilgin E; Bölek EÇ; Karadağ Ö; Bilgen ŞA; Kiraz S; Ertenli İ; Kalyoncu U
    Rheumatol Int; 2023 Jan; 43(1):147-156. PubMed ID: 36129541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor Necrosis Factor-α Inhibition in Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis: Treatment Response, Drug Survival, and Patient Outcome.
    Corli J; Flipo RM; Philippe P; Bera-Louville A; Béhal H; Wibaux C; Paccou J
    J Rheumatol; 2015 Dec; 42(12):2376-82. PubMed ID: 26568593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.